{{chembox
| Verifiedfields = changed
| verifiedrevid = 446670426
| ImageFile=Molsidomine.svg
| IUPACName=1-Ethoxy-''N''-(3-morpholino-5-oxadiazol-3-iumyl)methanimidate
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D46583G77X
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4090
| InChI = 1/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
| InChIKey = XLFWDASMENKTKL-UHFFFAOYAC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XLFWDASMENKTKL-UHFFFAOYSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=25717-80-0
| PubChem=5353788
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1256353
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01320
| SMILES = [O-]C(OCC)=Nc2on[n+](N1CCOCC1)c2
}}
|Section2={{Chembox Properties
| Formula=C<sub>9</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>
| MolarMass=242.23 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section6={{Chembox Pharmacology
| ATCCode_prefix = C01
| ATCCode_suffix = DX12
}}
|Section7={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Molsidomine''' is an orally active, long acting [[vasodilator|vasodilating]] [[drug]]. Molsidomine is [[drug metabolism|metabolized]] in the [[liver]] to the [[active metabolite]] [[linsidomine]]. Linsidomine is an unstable compound that releases [[nitric oxide]] (NO) upon decay as the actual vasodilating compound.<ref>{{Cite journal 
| last1 = Rosenkranz | first1 = B. 
| last2 = Winkelmann | first2 = B. R. 
| last3 = Parnham | first3 = M. J. 
| title = Clinical pharmacokinetics of molsidomine 
| journal = Clinical pharmacokinetics 
| volume = 30 
| issue = 5 
| pages = 372–384 
| year = 1996 
| pmid = 8743336
| doi=10.2165/00003088-199630050-00004
}}</ref>

==Release of nitric oxide<ref>{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|page=558|isbn=3-8047-1763-2}}</ref>==
[[File:Activation of molsidomine.svg|thumb|center|700px]]
== Chemistry==
Molsidomine as well as linsidomine are [[sydnone imine]]s, a class of [[mesoionic]] [[heterocyclic compound|heterocyclic]] [[aromatic]] [[chemical compound]]s.
==Synthesis==
A [[mesoionic]] [[sydnone]] is active as an antianginal agent.
[[File:Molsidomine synthesis.svg|thumb|center|700px|Molsidomine synthesis:<ref>[http://ci.nii.ac.jp/els/110003632546.pdf?id=ART0004139913&type=pdf&lang=en&host=cinii&order_no=&ppv_type=0&lang_sw=&no=1438091494&cp= Chemical & pharmaceutical bulletin 19(1), 72-79, 1971-01-25.]</ref>]]
Its synthesis starts by reacting 1-aminomorpholine with formaldehyde and hydrogen cyanide to give '''2'''. [[Nitrosation]] gives the N-nitroso analog ('''3''') which cyclizes to the [[sydnone]] ('''4''') on treatment with anhydrous acid. Formation of the ethyl urethane is then made possible by reacting [[Linsidomine]] with [[Ethyl chloroformate]].

== See also ==
* [[Nitric oxide]]
* [[Nitrate (pharmacology)]]
* [[Vasodilator]]

==References==
{{Reflist}}


{{Vasodilators used in cardiac diseases}}
{{Nitric oxide signaling}}

[[Category:Vasodilators]]
[[Category:Morpholines]]
[[Category:Carbamates]]
[[Category:Oxadiazoles]]

{{cardiovascular-drug-stub}}